PURPOSE: After reports of malaise in infants immediately after the oral administration of two brands of vitamin D solutions, a "Dear Doctor letter" (DDL) containing recommendations for the administration of vitamin D was sent to all French paediatricians and pharmacies and a large number of French general practitioners (GPs) with a predominantly paediatric practice. The DDL and a press release were published on the French Medicines Agency website and distributed via a mailing list. The objective of this study was to assess the effectiveness of such a DDL and to collect the opinions of healthcare professionals on the best way to provide them with information. METHODS: A questionnaire was sent to a national random sample of 145 paediatricians, 680 GPs and 230 pharmacists. RESULTS: Only 49% of responding paediatricians, 48% of GPs and 67% of pharmacists were aware of the warning. Among the participating healthcare professionals aware of the warning and who prescribed/dispensed these vitamins, 50% of paediatricians and 68% of GPs stated that they had changed their prescribing behaviour, and 68% of pharmacists stated that they had modified their advice when dispensing. According to the responding healthcare professionals, postal letters remained the best way to issue safety warnings. Some of the respondents suggested that the DDL be more distinctive in terms of being a DDL and that the information be more widely disseminated to other stakeholders involved in the healthcare system. CONCLUSIONS: This survey of a national random sample of healthcare professionals revealed that many of the respondents paid little attention to the DDL and were therefore unlikely to change their practices. A potential supplementary method for disseminating recommendations for medicine administration could be to apply stickers on medicine boxes, as this approach has the additional advantage of directly informing the concerned population, i.e. the parents.
PURPOSE: After reports of malaise in infants immediately after the oral administration of two brands of vitamin D solutions, a "Dear Doctor letter" (DDL) containing recommendations for the administration of vitamin D was sent to all French paediatricians and pharmacies and a large number of French general practitioners (GPs) with a predominantly paediatric practice. The DDL and a press release were published on the French Medicines Agency website and distributed via a mailing list. The objective of this study was to assess the effectiveness of such a DDL and to collect the opinions of healthcare professionals on the best way to provide them with information. METHODS: A questionnaire was sent to a national random sample of 145 paediatricians, 680 GPs and 230 pharmacists. RESULTS: Only 49% of responding paediatricians, 48% of GPs and 67% of pharmacists were aware of the warning. Among the participating healthcare professionals aware of the warning and who prescribed/dispensed these vitamins, 50% of paediatricians and 68% of GPs stated that they had changed their prescribing behaviour, and 68% of pharmacists stated that they had modified their advice when dispensing. According to the responding healthcare professionals, postal letters remained the best way to issue safety warnings. Some of the respondents suggested that the DDL be more distinctive in terms of being a DDL and that the information be more widely disseminated to other stakeholders involved in the healthcare system. CONCLUSIONS: This survey of a national random sample of healthcare professionals revealed that many of the respondents paid little attention to the DDL and were therefore unlikely to change their practices. A potential supplementary method for disseminating recommendations for medicine administration could be to apply stickers on medicine boxes, as this approach has the additional advantage of directly informing the concerned population, i.e. the parents.
Authors: Jeff Jianfei Guo; Suellen Curkendall; Judith K Jones; Daniel Fife; Earl Goehring; Dewei She Journal: Pharmacoepidemiol Drug Saf Date: 2003-06 Impact factor: 2.890
Authors: Peter G M Mol; Sabine M J M Straus; Sigrid Piening; Jonie T N de Vries; Pieter A de Graeff; Flora M Haaijer-Ruskamp Journal: Drug Saf Date: 2010-06-01 Impact factor: 5.606
Authors: Robert J Cluxton; Zili Li; Pamela C Heaton; Sheila R Weiss; Ilene H Zuckerman; Charles J Moomaw; Van Doren Hsu; Evelyn M Rodriguez Journal: Pharmacoepidemiol Drug Saf Date: 2005-01 Impact factor: 2.890
Authors: Sigrid Piening; Pieter A de Graeff; Sabine M J M Straus; Flora M Haaijer-Ruskamp; Peter G M Mol Journal: Drug Saf Date: 2013-09 Impact factor: 5.606
Authors: Kristina Lohmann; Julia Ferber; Alexander Francesco Josef Send; Walter Emil Haefeli; Hanna Marita Seidling Journal: Eur J Clin Pharmacol Date: 2014-01-28 Impact factor: 2.953
Authors: André Said; Leonard Freudewald; Natalie Parrau; Matthias Ganso; Martin Schulz Journal: Medicine (Baltimore) Date: 2021-03-19 Impact factor: 1.817
Authors: Lise M Bjerre; Simon Parlow; David de Launay; Matthew Hogel; Cody D Black; Donald R Mattison; Jeremy M Grimshaw; Margaret C Watson Journal: BMJ Open Date: 2018-10-08 Impact factor: 2.692
Authors: Ushma Mehta; Mariette Smith; Emma Kalk; Helen Hayes; Annoesjka Swart; Lawrence Tucker; Renier Coetzee; Andrew Boulle; Marc Blockman Journal: Drug Saf Date: 2021-01 Impact factor: 5.606